IL17A and psoriasis: Inspiringly, Bruton's tyrosine kinase inhibitor was reported to suppress IMQ‐induced psoriasis‐like inflammation through regulation of IL‐23/IL‐17A in innate immune cells,50 which enriches the recognition of psoriasis's pathogenesis and treatment idea.